Breaking News, Financial News

Financial Reports: Charles River 2Q11

Research model revenues up, but preclinical revenues fall

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Charles River 2Q11 2Q Revenues: $288 million (flat) 2Q Earnings: $34 million (+125%) YTD Revenues: $574 million (-1%) YTD Earnings: $63 million (+105%) Comments: Revenues were up 7% in 2Q for the Research Models and Services (RMS) segment, to $167 million. Currency exchange accounted for all but 1.3% of that increase. Preclinical Services (PCS) revenues were down 9% to $110 million, due to a drop in demand by large pharma clients. Currency exchange accounted for 3% of the decline. For YTD, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters